ArticleAmerican journal of translational research2023
Effects of methotrexate combined with tocilizumab on growth and bone metabolism in children with juvenile idiopathic arthritis.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to determine the effects of methotrexate combined with tocilizumab on growth and bone metabolism in children with juvenile idiopathic arthritis (JIA).
methodsThe medical records of 112 children with JIA treated in the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine from March 2019 to June 2021 were collected and analyzed retrospectively. There were 51 patients treated with methotrexate alone who were assigned to the control group. The remaining 61 patients treated with methotrexate combined with tocilizumab were assigned to the observation group. The efficacy, adverse reactions, and growth after the treatment were compared between the two groups. A multiple variable logistic regression analysis was performed to analyze the independent risk factors affecting the efficacy on children.
resultsThe observation group had significantly better improvement rates of Pediatric American College of Rheumatology Criteria (ACR) Ped 50 and ACR Ped 70 than the control group (P<0.05). The incidence of adverse reactions in the two groups was not significantly different (P>0.05). After therapy, the observation group showed significantly lower C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels than the control group (P<0.001). Significantly higher Z values of the height and weight was shown in the observation group compared to the control group (P<0.01). The observation group showed significantly lower levels of receptor activator of nuclear factor κB ligand (RANKL) and β-collagen degradation products (β-CTX) than the control group. A significantly lower osteoprotegerin (OPG) level was seen in the observation group when compared to the control group (P<0.001). A multivariate logistic regression analysis showed that a longer course of disease, disease type, and treatment with methotrexate alone were the independent risk factors for the failure to improve the efficacy on patients (P<0.05).
conclusionMethotrexate combined with tocilizumab can deliver good efficacy on children with JIA, quickly alleviate their clinical symptoms and laboratory indicators, and control the disease progress. It is safe because it will not increase the incidence of adverse reactions.
Indexed as
Identifiers
37303692PMC10250976W4380291143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.